XTAEINCR
Market cap79mUSD
Dec 26, Last price
615.80ILS
1D
0.02%
1Q
-12.87%
Jan 2017
148.06%
IPO
-100.00%
Name
InterCure Ltd
Chart & Performance
Profile
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 355,553 -8.52% | 388,684 76.93% | 219,677 237.78% | |||||||
Cost of revenue | 337,083 | 331,551 | 183,720 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 18,470 | 57,133 | 35,957 | |||||||
NOPBT Margin | 5.19% | 14.70% | 16.37% | |||||||
Operating Taxes | 2,248 | 93 | 11,441 | |||||||
Tax Rate | 12.17% | 0.16% | 31.82% | |||||||
NOPAT | 16,222 | 57,040 | 24,516 | |||||||
Net income | (61,959) -238.24% | 44,819 514.30% | 7,296 -120.24% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 128,730 | |||||||||
BB yield | -13.24% | |||||||||
Debt | ||||||||||
Debt current | 92,834 | 132,374 | 75,588 | |||||||
Long-term debt | 128,124 | 150,237 | 58,002 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | 841 | 1,025 | 223 | |||||||
Net debt | 117,710 | 7,252 | (65,522) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (53,631) | 51,267 | 25,020 | |||||||
CAPEX | (2,619) | (19,742) | (14,029) | |||||||
Cash from investing activities | 4,773 | (142,497) | (65,210) | |||||||
Cash from financing activities | (82,889) | 120,446 | 203,057 | |||||||
FCF | (69,030) | (32,321) | (19,079) | |||||||
Balance | ||||||||||
Cash | 101,326 | 232,794 | 196,547 | |||||||
Long term investments | 1,922 | 42,565 | 2,565 | |||||||
Excess cash | 85,470 | 255,925 | 188,128 | |||||||
Stockholders' equity | 457,062 | 512,936 | 450,650 | |||||||
Invested Capital | 568,110 | 521,737 | 380,201 | |||||||
ROIC | 2.98% | 12.65% | 7.65% | |||||||
ROCE | 2.83% | 7.35% | 6.33% | |||||||
EV | ||||||||||
Common stock shares outstanding | 45,573 | 45,353 | 46,920 | |||||||
Price | 4.63 -61.66% | 12.08 -41.70% | 20.72 26.72% | |||||||
Market cap | 211,047 -61.48% | 547,859 -43.65% | 972,182 134.12% | |||||||
EV | 330,707 | 575,283 | 917,823 | |||||||
EBITDA | 31,636 | 68,832 | 43,350 | |||||||
EV/EBITDA | 10.45 | 8.36 | 21.17 | |||||||
Interest | 24,219 | 14,689 | 5,045 | |||||||
Interest/NOPBT | 131.13% | 25.71% | 14.03% |